These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10217925)

  • 1. Clinical utility of CERAD neuropsychological battery in elderly Jamaicans.
    Unverzagt FW; Morgan OS; Thesiger CH; Eldemire DA; Luseko J; Pokuri S; Hui SL; Hall KS; Hendrie HC
    J Int Neuropsychol Soc; 1999 Mar; 5(3):255-9. PubMed ID: 10217925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A total score for the CERAD neuropsychological battery.
    Chandler MJ; Lacritz LH; Hynan LS; Barnard HD; Allen G; Deschner M; Weiner MF; Cullum CM
    Neurology; 2005 Jul; 65(1):102-6. PubMed ID: 16009893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe).
    Stein J; Luppa M; Luck T; Maier W; Wagner M; Daerr M; van den Bussche H; Zimmermann T; Köhler M; Bickel H; Mösch E; Weyerer S; Kaufeler T; Pentzek M; Wiese B; Wollny A; König HH; Riedel-Heller SG
    Am J Geriatr Psychiatry; 2012 Jan; 20(1):84-97. PubMed ID: 22183013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the CERAD-NP on diagnosis of cognitive deficiencies in late onset depression and Alzheimer's disease.
    Künig G; Jäger M; Stief V; Kaldune A; Urbaniok F; Endrass J
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):911-6. PubMed ID: 16927401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M; Laatu S; Martikainen K; Marttila R
    Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Practical application of the CERAD test battery as a neuropsychological dementia screening test].
    Satzger W; Hampel H; Padberg F; Bürger K; Nolde T; Ingrassia G; Engel RR
    Nervenarzt; 2001 Mar; 72(3):196-203. PubMed ID: 11268764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries.
    Lee JH; Lee KU; Lee DY; Kim KW; Jhoo JH; Kim JH; Lee KH; Kim SY; Han SH; Woo JI
    J Gerontol B Psychol Sci Soc Sci; 2002 Jan; 57(1):P47-53. PubMed ID: 11773223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Mild Cognitive Impairment Using the Thai Version of the Consortium to Establish a Registry for Alzheimer's Disease Tests: A Multivariate and Machine Learning Study.
    Tunvirachaisakul C; Supasitthumrong T; Tangwongchai S; Hemrunroj S; Chuchuen P; Tawankanjanachot I; Likitchareon Y; Phanthumchinda K; Sriswasdi S; Maes M
    Dement Geriatr Cogn Disord; 2018; 45(1-2):38-48. PubMed ID: 29617684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB).
    Mistridis P; Egli SC; Iverson GL; Berres M; Willmes K; Welsh-Bohmer KA; Monsch AU
    Eur Arch Psychiatry Clin Neurosci; 2015 Aug; 265(5):407-17. PubMed ID: 25555899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance on the CERAD neuropsychology battery of two samples of Japanese-American elders: norms for persons with and without dementia.
    Fillenbaum GG; McCurry SM; Kuchibhatla M; Masaki KH; Borenstein AR; Foley DJ; Heyman A; Larson EB; White L
    J Int Neuropsychol Soc; 2005 Mar; 11(2):192-201. PubMed ID: 15966108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CERAD Neuropsychological Assessment Battery Is Sensitive to Alcohol-Related Cognitive Deficiencies in Elderly Patients: A Retrospective Matched Case-Control Study.
    Kaufmann L; Huber S; Mayer D; Moeller K; Marksteiner J
    J Int Neuropsychol Soc; 2018 Apr; 24(4):360-371. PubMed ID: 29103404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the CERAD neuropsychological battery be used to assess cognitive impairment in Parkinson's disease?
    Camargo CHF; Bronzini A; Tolentino ES; Medyk C; Schultz-Pereira GL
    Arq Neuropsiquiatr; 2018 Mar; 76(3):145-149. PubMed ID: 29809231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease.
    Berres M; Monsch AU; Bernasconi F; Thalmann B; Stähelin HB
    Stud Health Technol Inform; 2000; 77():195-9. PubMed ID: 11187541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive decline in the behavioral variant of frontotemporal dementia.
    Diehl-Schmid J; Bornschein S; Pohl C; Förstl H; Kurz A; Jahn T
    Int Psychogeriatr; 2011 Mar; 23(2):230-7. PubMed ID: 20836915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A normative study of the CERAD neuropsychological assessment battery in the Korean elderly.
    Lee DY; Lee KU; Lee JH; Kim KW; Jhoo JH; Kim SY; Yoon JC; Woo SI; Ha J; Woo JI
    J Int Neuropsychol Soc; 2004 Jan; 10(1):72-81. PubMed ID: 14751009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H; Addneuromed Consortium
    J Alzheimers Dis; 2010; 22(4):1089-97. PubMed ID: 20930314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of elderly African American and White community residents on the CERAD Neuropsychological Battery.
    Fillenbaum GG; Heyman A; Huber MS; Ganguli M; Unverzagt FW
    J Int Neuropsychol Soc; 2001 May; 7(4):502-9. PubMed ID: 11396552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age, education and gender in the Consortium to Establish a Registry for the Alzheimer's Disease (CERAD)-Neuropsychological Assessment Battery for Cantonese-speaking Chinese elders.
    Liu KP; Kuo MC; Tang KC; Chau AW; Ho IH; Kwok MP; Chan WC; Choi RH; Lam NC; Chu MM; Chu LW
    Int Psychogeriatr; 2011 Dec; 23(10):1575-81. PubMed ID: 21729408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease.
    Karrasch M; Sinervä E; Grönholm P; Rinne J; Laine M
    Acta Neurol Scand; 2005 Mar; 111(3):172-9. PubMed ID: 15691286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.